Ruthigen Inc. (RTGN) 6.37 $RTGN
Ruthigen Announces Partial Exercise of Underwriters' Option to Purchase Additional Shares
PR Newswire - Mon May 05, 6:00AM CDT
Ruthigen, Inc., (NASDAQ: RTGN), a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications, today announced that the underwriters of Ruthigen's recently completed initial public offering have partially exercised their option to purchase additional shares of common stock. The underwriters have purchased an additional 154,290 shares from Ruthigen pursuant to the option.
Ruthigen Submits Investigational New Drug (IND) Application for Clinical Trial of RUT58-60
PR Newswire - Fri May 02, 6:00AM CDT
Ruthigen, Inc., (NASDAQ: RTGN), a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications, today announced that the Company has submitted an Investigational New Drug (IND) Application to the U.S. Food and Drug Administration (FDA) for its lead drug candidate RUT58-60. The Company plans to initiate its combined Phase 1/2 clinical trial for RUT58-60, entitled: "A Phase 1/2 Double Blind, Randomized Controlled Study to Evaluate the Safety and Efficacy of RUT58-60 Lavage Following Abdominal Surgery as an Adjunctive Therapy to Prophylactic Systemic Antibiotics," as early as July 2014.
Oculus Innovative Sciences Announces Board of Directors Restructuring Following Ruthigen IPO
GlobeNewswire - Wed Apr 02, 8:43AM CDT
-- Board Committees Restructured
Ruthigen Announces Pricing of Initial Public Offering
PR Newswire - Fri Mar 21, 8:39AM CDT
Ruthigen, Inc., (NASDAQ: RTGN), a biopharmaceutical company focused on the discovery, development and commercialization of pharmaceutical-grade hypochlorous acid, or HOCl, based therapeutics designed to prevent and treat infection in invasive applications, today announced the pricing of its initial public offering of 2,650,000 units, which reflects an increase in the originally anticipated number of units, with each unit consisting of one share of common stock and one Series A Warrant. Each Series A Warrant is exercisable for one share of common stock and one Series B Warrant to purchase one share of common stock. All of the units are being offered by Ruthigen at an initial public offering price of $7.25 per unit. The units will not be certificated and the shares of common stock and Series A Warrants may be transferred separately immediately upon issuance.
Oculus Innovative Sciences, Inc. to Raise $1.35 Million in Registered Direct Offering
GlobeNewswire - Fri Feb 21, 9:00PM CST
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) announced today that it has entered into definitive agreements with two life sciences-focused institutional investors for the sale of 450,620 units, consisting of shares of common stock, and Series A and Series B warrants, at a per unit price of $3.00 per share. The total amount sold consisted of a combination of: (1) 450,620 shares of its common stock; (2) Series A warrants to purchase up to 450,620 shares of common stock at an exercise price of $3.00 per share and a term of five years; and (3) Series B warrants to purchase up to 1,400,000 shares of common stock at an exercise price of $3.63 per share. The Series B warrants are not exercisable for six months following the closing of the IPO and have a term of 18 months. The Series B warrants have not vested and will not vest until the completion of the initial public offering (IPO) by the company's subsidiary, Ruthigen, Inc. The Series B warrants terminate on March 31, 2014, if the Ruthigen IPO has not occurred by that date.
Oculus Innovative Sciences Announces Completion of Agreements Required for IPO by Company's Subsidiary, Ruthigen, Inc.
GlobeNewswire - Thu Feb 06, 3:05PM CST
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), today announced that as of January 31, 2014, Oculus has entered into certain new and amended agreements with its wholly owned subsidiary, Ruthigen Inc., which are required for Ruthigen's continued IPO process.
Ruthigen Announces Partial Exercise of Underwriters' Option to Purchase Additional Shares
PR Newswire - Mon May 05, 6:00AM CDT
Ruthigen, Inc., (NASDAQ: RTGN), a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications, today announced that the underwriters of Ruthigen's recently completed initial public offering have partially exercised their option to purchase additional shares of common stock. The underwriters have purchased an additional 154,290 shares from Ruthigen pursuant to the option.
Ruthigen Submits Investigational New Drug (IND) Application for Clinical Trial of RUT58-60
PR Newswire - Fri May 02, 6:00AM CDT
Ruthigen, Inc., (NASDAQ: RTGN), a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications, today announced that the Company has submitted an Investigational New Drug (IND) Application to the U.S. Food and Drug Administration (FDA) for its lead drug candidate RUT58-60. The Company plans to initiate its combined Phase 1/2 clinical trial for RUT58-60, entitled: "A Phase 1/2 Double Blind, Randomized Controlled Study to Evaluate the Safety and Efficacy of RUT58-60 Lavage Following Abdominal Surgery as an Adjunctive Therapy to Prophylactic Systemic Antibiotics," as early as July 2014.
Oculus Innovative Sciences Announces Board of Directors Restructuring Following Ruthigen IPO
GlobeNewswire - Wed Apr 02, 8:43AM CDT
-- Board Committees Restructured
Ruthigen Announces Pricing of Initial Public Offering
PR Newswire - Fri Mar 21, 8:39AM CDT
Ruthigen, Inc., (NASDAQ: RTGN), a biopharmaceutical company focused on the discovery, development and commercialization of pharmaceutical-grade hypochlorous acid, or HOCl, based therapeutics designed to prevent and treat infection in invasive applications, today announced the pricing of its initial public offering of 2,650,000 units, which reflects an increase in the originally anticipated number of units, with each unit consisting of one share of common stock and one Series A Warrant. Each Series A Warrant is exercisable for one share of common stock and one Series B Warrant to purchase one share of common stock. All of the units are being offered by Ruthigen at an initial public offering price of $7.25 per unit. The units will not be certificated and the shares of common stock and Series A Warrants may be transferred separately immediately upon issuance.
Oculus Innovative Sciences, Inc. to Raise $1.35 Million in Registered Direct Offering
GlobeNewswire - Fri Feb 21, 9:00PM CST
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) announced today that it has entered into definitive agreements with two life sciences-focused institutional investors for the sale of 450,620 units, consisting of shares of common stock, and Series A and Series B warrants, at a per unit price of $3.00 per share. The total amount sold consisted of a combination of: (1) 450,620 shares of its common stock; (2) Series A warrants to purchase up to 450,620 shares of common stock at an exercise price of $3.00 per share and a term of five years; and (3) Series B warrants to purchase up to 1,400,000 shares of common stock at an exercise price of $3.63 per share. The Series B warrants are not exercisable for six months following the closing of the IPO and have a term of 18 months. The Series B warrants have not vested and will not vest until the completion of the initial public offering (IPO) by the company's subsidiary, Ruthigen, Inc. The Series B warrants terminate on March 31, 2014, if the Ruthigen IPO has not occurred by that date.
Oculus Innovative Sciences Announces Completion of Agreements Required for IPO by Company's Subsidiary, Ruthigen, Inc.
GlobeNewswire - Thu Feb 06, 3:05PM CST
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), today announced that as of January 31, 2014, Oculus has entered into certain new and amended agreements with its wholly owned subsidiary, Ruthigen Inc., which are required for Ruthigen's continued IPO process.
